Ekaterina Dadachova Selected Research

Viral Antigens

2/2011	Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
11/2010	Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.
2/2010	The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
10/2007	Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology.
6/2007	Targeting the virus with radioimmunotherapy in virus-associated cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ekaterina Dadachova Research Topics

Disease

59	Neoplasms (Cancer) 05/2024 - 05/2002
22	Infections 11/2023 - 05/2007
19	Melanoma (Melanoma, Malignant) 07/2023 - 10/2004
19	Communicable Diseases (Infectious Diseases) 01/2023 - 09/2003
8	Breast Neoplasms (Breast Cancer) 03/2017 - 01/2003
7	Experimental Melanoma 11/2020 - 04/2006
6	Virus Diseases (Viral Diseases) 01/2023 - 09/2007
6	Mycoses (Diseases, Fungus) 01/2022 - 02/2004
5	Osteosarcoma (Osteogenic Sarcoma) 05/2024 - 12/2016
5	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2019 - 10/2007
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2019 - 05/2013
3	Cryptococcosis 01/2012 - 04/2009
3	Anthrax 06/2010 - 10/2008
2	Inflammation (Inflammations) 04/2024 - 01/2014
2	Bacterial Infections (Bacterial Infection) 11/2023 - 05/2006
2	COVID-19 01/2023 - 01/2021
2	Invasive Fungal Infections 01/2023 - 08/2020
2	Neurocognitive Disorders (Clerambault Syndrome) 02/2016 - 08/2014
2	Body Weight (Weight, Body) 02/2014 - 12/2010
1	Disease Progression 04/2024
1	Multiple Sclerosis 04/2024
1	Autoimmune Diseases (Autoimmune Disease) 04/2024
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/2024
1	Mucormycosis 01/2023
1	Obesity 01/2023
1	Wounds and Injuries (Trauma) 12/2022
1	Dysbiosis 12/2022
1	Endocarditis 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Blastomycosis 01/2020
1	Retinoblastoma (Glioblastoma, Retinal) 10/2019
1	Testicular Neoplasms (Testicular Cancer) 09/2019
1	Multiple Myeloma 01/2019
1	Starvation 03/2017

Drug/Important Bio-Agent (IBA)

30	Monoclonal AntibodiesIBA 01/2023 - 05/2002
29	AntibodiesIBA 05/2024 - 09/2004
22	Radioisotopes (Radionuclides)IBA 04/2024 - 08/2005
22	Melanins (Melanin)IBA 07/2023 - 10/2004
14	AntigensIBA 01/2023 - 09/2004
6	Oncogene Proteins (Oncogene Protein)IBA 10/2019 - 10/2005
6	Peptides (Polypeptides)IBA 05/2016 - 04/2006
5	Complement System Proteins (Complement)IBA 08/2022 - 04/2013
5	Therapeutic UsesIBA 01/2019 - 01/2004
5	Viral AntigensIBA 02/2011 - 06/2007
4	Lutetium-177IBA 05/2024 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2007
4	Immunoglobulin G (IgG)IBA 07/2019 - 09/2007
4	Indicators and Reagents (Reagents)IBA 07/2019 - 09/2004
4	Immunoglobulin M (IgM)IBA 02/2013 - 09/2007
3	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 05/2012
3	RadiopharmaceuticalsIBA 11/2023 - 01/2022
3	Anti-Bacterial Agents (Antibiotics)IBA 02/2023 - 12/2009
3	Insulin (Novolin)FDA Link 05/2021 - 12/2016
2	lintuzumabIBA 10/2022 - 01/2021
2	Bismuth-213IBA 08/2020 - 10/2018
2	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 02/2014
2	Rhenium-188IBA 10/2018 - 01/2016
2	Anti-Infective Agents (Microbicides)IBA 10/2018 - 11/2005
2	6-hydrazinopyridine-3-carboxylic acidIBA 10/2011 - 11/2007
2	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2011 - 08/2010
2	Surface Antigens (Surface Antigen)IBA 01/2011 - 12/2006
2	benzyloxycarbonylleucyl-leucyl-leucine aldehydeIBA 11/2010 - 02/2010
2	Proteasome InhibitorsIBA 11/2010 - 02/2010
2	alpha-MSHIBA 05/2010 - 12/2006
2	Biological Warfare AgentsIBA 10/2008 - 09/2004
2	Viral ProteinsIBA 10/2007 - 06/2007
2	Immunoglobulin Fab FragmentsIBA 09/2007 - 12/2006
2	SymportersIBA 10/2005 - 03/2004
2	sodium-iodide symporter (sodium iodide symporter)IBA 10/2005 - 03/2004
2	Glucose (Dextrose)FDA LinkGeneric 02/2005 - 01/2003
1	Actinium-225IBA 05/2024
1	Caspase 3 (Caspase-3)IBA 05/2024
1	myelin oligodendrocyte glycoprotein (35-55)IBA 04/2024
1	AutoantigensIBA 04/2024
1	SteroidsIBA 01/2023
1	beta-1,3-glucanIBA 01/2023
1	Antifungal AgentsIBA 01/2023
1	Antimicrobial PeptidesIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2021
1	venetoclaxIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 11/2020
1	Chimeric Antigen ReceptorsIBA 09/2020
1	beta-GlucansIBA 01/2020
1	daratumumabIBA 01/2019
1	Growth Factor ReceptorsIBA 01/2019
1	N-hydroxysuccinimide S-acetylthioacetate (SATA)IBA 10/2018
1	Chelating AgentsIBA 10/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2017
1	Phosphorus (Red Phosphorus)IBA 03/2017
1	Epidermal Growth Factor (EGF)IBA 03/2017
1	Mixed Function Oxygenases (Monooxygenases)IBA 03/2017
1	EnzymesIBA 03/2017

Therapy/Procedure

47	Therapeutics 04/2024 - 01/2003
46	Radioimmunotherapy 08/2023 - 04/2004
4	Immunotherapy 08/2022 - 05/2016
2	Precision Medicine 04/2024 - 07/2023
2	Drug Therapy (Chemotherapy) 02/2013 - 04/2009
2	Radiotherapy 12/2010 - 03/2004
1	Catheters 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 09/2020